Hormone receptor status and pathologic response of HER2-positive breast cancer treated with neoadjuvant chemotherapy and trastuzumab.

MLA

F. Peintinger, et al. “Hormone Receptor Status and Pathologic Response of HER2-Positive Breast Cancer Treated with Neoadjuvant Chemotherapy and Trastuzumab.” Annals of Oncology, vol. 19, no. 12, Dec. 2008, p. 2020. EBSCOhost, https://doi.org/10.1093/annonc/mdn427.

APA

F. Peintinger, A. U. Buzdar, H. M. Kuerer, J. A. Mejia, C. Hatzis, A. M. Gonzalez-Angulo, L. Pusztai, F. J. Esteva, S. S. Dawood, M. C. Green, G. N. Hortobagyi, & W. F. Symmans. (2008). Hormone receptor status and pathologic response of HER2-positive breast cancer treated with neoadjuvant chemotherapy and trastuzumab. Annals of Oncology, 19(12), 2020. https://doi.org/10.1093/annonc/mdn427

Chicago

F. Peintinger, A. U. Buzdar, H. M. Kuerer, J. A. Mejia, C. Hatzis, A. M. Gonzalez-Angulo, L. Pusztai, et al. 2008. “Hormone Receptor Status and Pathologic Response of HER2-Positive Breast Cancer Treated with Neoadjuvant Chemotherapy and Trastuzumab.” Annals of Oncology 19 (12): 2020. doi:10.1093/annonc/mdn427.